A psychedelic therapy screening assessment is the structured clinical process that determines whether you are a suitable candidate for psilocybin or similar modalities. For high-performing individuals, it covers psychiatric history, cardiovascular health, current...
The FDA rejected Lykos Therapeutics’ application for MDMA-assisted therapy for PTSD in August 2024, and as of mid-2026 that decision stands. MDMA remains a Schedule I substance in the United States, meaning the only legal access pathways are through active...
This psychedelic therapy FAQ compiles the most common and most important questions from people seriously considering psilocybin or other psychedelic-assisted approaches. The answers here are grounded in current clinical research, verified legal data, and practical...
Research from Johns Hopkins, NYU, and Imperial College London shows that psilocybin long term effects on depression and anxiety can persist well beyond the session itself, with some studies tracking sustained improvements at 6, 12, and even 4.5 years post-treatment....
The JOM11 psychedelic executive program is JourneyOM’s structured, concierge-level pathway for senior leaders who want to address burnout, cognitive rigidity, or performance plateaus through professionally supported psychedelic therapy. Built around eleven...
The two most widely followed microdosing protocols are the Fadiman protocol (one day on, two days off) and the Stamets Stack (four or five days on, two or three days off, with lion’s mane and niacin added). Both emerged from citizen science rather than clinical...
